Bertil  Lindmark net worth and biography

Bertil Lindmark Biography and Net Worth

Insider of Galecto
Bertil Lindmark has had an extensive and successful career in the pharmaceutical industry, building up broad clinical development and regulatory experience globally, and significant expertise in research and development in both large and small pharmaceutical organizations. As Global VP Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca, Bertil led development of Symbicort, one of the worlds’ leading respiratory brands, and many other respiratory and gastro-intestinal products. From  2010, he headed Global R&D at Almirall, involving 500 staff and the successful development and approval of several new drugs in the respiratory, gastro-intestinal, neuroscience and dermatological fields. In 2015 he joined ASLAN Pharmaceuticals in Singapore with a focus on cancer and atopic skin and lung diseases. Bertil holds an MD from Lund University, Sweden with specialties in internal medicine and gastroenterology, and obtained his PhD in molecular epidemiology from Lund University. In 2019, he was appointed visiting Professor Innovation and Entrepreneurship at the Institute of Medicine at Gothenburg University, Sweden.

What is Bertil Lindmark's net worth?

The estimated net worth of Bertil Lindmark is at least $1,560.00 as of June 28th, 2021. Lindmark owns 2,000 shares of Galecto stock worth more than $1,560 as of March 28th. This net worth estimate does not reflect any other assets that Lindmark may own. Learn More about Bertil Lindmark's net worth.

How do I contact Bertil Lindmark?

The corporate mailing address for Lindmark and other Galecto executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Galecto can also be reached via phone at 45-7070-5210. Learn More on Bertil Lindmark's contact information.

Has Bertil Lindmark been buying or selling shares of Galecto?

Bertil Lindmark has not been actively trading shares of Galecto in the last ninety days. Most recently, on Tuesday, March 22nd, Bertil Lindmark bought 14,604 shares of Galecto stock. The stock was acquired at an average cost of $2.16 per share, with a total value of $31,544.64. Learn More on Bertil Lindmark's trading history.

Who are Galecto's active insiders?

Galecto's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Galecto's active insiders.

Are insiders buying or selling shares of Galecto?

In the last year, insiders at the sold shares 8 times. They sold a total of 644,391 shares worth more than $1,611,457.74. The most recent insider tranaction occured on July, 31st when Major Shareholder Orbimed Advisors Llc sold 209,400 shares worth more than $628,200.00. Insiders at Galecto own 12.1% of the company. Learn More about insider trades at Galecto.

Information on this page was last updated on 7/31/2023.

Bertil Lindmark Insider Trading History at Galecto

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2022Buy14,604$2.16$31,544.64View SEC Filing Icon  
6/28/2021Buy2,000$5.26$10,520.002,000View SEC Filing Icon  
See Full Table

Bertil Lindmark Buying and Selling Activity at Galecto

This chart shows Bertil Lindmark's buying and selling at Galecto by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Galecto Company Overview

Galecto logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $0.78
Low: $0.77
High: $0.82

50 Day Range

MA: $0.71
Low: $0.60
High: $0.89

2 Week Range

Now: $0.78
Low: $0.50
High: $3.70

Volume

128,972 shs

Average Volume

257,390 shs

Market Capitalization

$21.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22